Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysis

BACKGROUND: Although 13-valent pneumococcal conjugate vaccine (PCV13) is available in China's private market, it has yet to be introduced into the National Immunization Programme (NIP) and is therefore not available to large parts of the population. This study aimed to estimate the cost-effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Xiaozhen, Garcia, Cristina, Wu, Dan, Knoll, Maria Deloria, Zhang, Haijun, Xu, Tingting, Jing, Rize, Yin, Zundong, Wahl, Brian, Fang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918781/
https://www.ncbi.nlm.nih.gov/pubmed/36785861
http://dx.doi.org/10.1016/j.lanwpc.2022.100666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918781/
https://www.ncbi.nlm.nih.gov/pubmed/36785861
http://dx.doi.org/10.1016/j.lanwpc.2022.100666

Ejemplares similares